Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Operating Leases: 2019-2024

Historic Operating Leases for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $72.4 million.

  • Kymera Therapeutics' Operating Leases fell 7.04% to $68.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.5 million, marking a year-over-year decrease of 7.04%. This contributed to the annual value of $72.4 million for FY2024, which is 5.98% down from last year.
  • Per Kymera Therapeutics' latest filing, its Operating Leases stood at $72.4 million for FY2024, which was down 5.98% from $77.0 million recorded in FY2023.
  • In the past 5 years, Kymera Therapeutics' Operating Leases registered a high of $77.0 million during FY2023, and its lowest value of $12.1 million during FY2022.
  • Its 3-year average for Operating Leases is $53.9 million, with a median of $72.4 million in 2024.
  • As far as peak fluctuations go, Kymera Therapeutics' Operating Leases fell by 15.15% in 2020, and later skyrocketed by 534.18% in 2023.
  • Over the past 5 years, Kymera Therapeutics' Operating Leases (Yearly) stood at $14.1 million in 2020, then dropped by 6.40% to $13.2 million in 2021, then fell by 8.15% to $12.1 million in 2022, then surged by 534.18% to $77.0 million in 2023, then declined by 5.98% to $72.4 million in 2024.